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Transcription factors (TFs) are gene regulatory proteins that are essential for an effective
regulation of the transcriptional machinery. Today, it is known that their expression plays
an important role in several types of cancer. Computational identification of key players
in specific cancer cell lines is still an open challenge in cancer research. In this study,
we present a systematic approach which combines colorectal cancer (CRC) cell lines,
namely 1638N-T1 and CMT-93, and well-established computational methods in order to
compare these cell lines on the level of transcriptional regulation as well as on a pathway
level, i.e., the cancer cell-intrinsic pathway repertoire. For this purpose, we firstly applied
the Trinity platform to detect signature genes, and then applied analyses of the geneXplain
platform to these for detection of upstream transcriptional regulators and their regulatory
networks. We created a CRC-specific position weight matrix (PWM) library based on the
TRANSFAC database (release 2014.1) to minimize the rate of false predictions in the
promoter analyses. Using our proposed workflow, we specifically focused on revealing
the similarities and differences in transcriptional regulation between the two CRC cell
lines, and report a number of well-known, cancer-associated TFs with significantly
enriched binding sites in the promoter regions of the signature genes. We show that,
although the signature genes of both cell lines show no overlap, theymay still be regulated
by common TFs in CRC. Based on our findings, we suggest that canonical Wnt signaling
is activated in 1638N-T1, but inhibited in CMT-93 through cross-talks of Wnt signaling
with the VDR signaling pathway and/or LXR-related pathways. Furthermore, our findings
provide indication of several master regulators being present such as MLK3 and Mapk1
(ERK2) whichmight be important in cell proliferation, migration, and invasion of 1638N-T1
and CMT-93, respectively. Taken together, we provide new insights into the invasive
potential of these cell lines, which can be used for development of effective cancer
therapy.
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1. INTRODUCTION
Cancer undergoes genetic and epigenetic changes through
which it acquires cellular and molecular characteristics during
invasive tumor growth. These changes allow the tumor cells
to evade the immune response, activate the microenvironment,
invade surrounding tissues and metastasize to distant sites. The
microenvironment plays an important role in this context as
it may trigger anti-tumor as well as pro-tumor signals (Gao
et al., 2014). Malignant tumor cells stimulate the production
and secretion of growth factors, cytokines and enzymes, thereby
recruiting the stroma and vasculature, which altogether results
in the conversion of a normal tumor-inhibiting into a tumor-
promoting microenvironment (Gao et al., 2014). In that
respect, tumor aggressiveness can be linked to processes such
as cell proliferation, growth, invasion, metastasis, survival as
well as inflammation which are regulated by multiple signal
transduction pathways. It has been suggested to summarize
known signal transduction reactions into about 17 signal
transduction pathways (Nebert, 2002). They are usually activated
by growth factor signals from the cell surface, and further
transmit the signal via transmembrane receptors to their target
intracellular effectors. In tumor cells, these pathways are often
dysregulated and harbor alterations in key components that can
function as driver mutations, i.e., either as activation mutations
(Ras, PI3K, Akt) or loss of tumor-suppressor gene function
(Pten). Several cancer drivers are important integral parts of these
pathways, such as receptor tyrosine kinases, and can be located
upstream in signal transduction cascades. Since protein kinases
propagate the signals along the cascade, they are considered
attractive drug targets for therapeutic intervention using specific
protein kinase inhibitors (Zwick et al., 2001; Torkamani et al.,
2009; Takeuchi and Ito, 2011; Casaletto and McClatchey, 2012).
To this end,many anticancer agents have been used in the context
of cancer therapy to account for the number of different pathways
(Casaletto and McClatchey, 2012).
The signaling pathways are interconnected and form an
elaborate network of pathways that receives signals from a
variety of growth factors to tightly regulate processes such as
transcription, cell growth, motility, differentiation, apoptosis,
and cytoskeletal organization. In addition, the outcome triggered
by the integrated signaling may differ between different cell
types. Therefore, knowledge on the cell type-specific pathways
including their architecture and complexity provides important
information on the tumor cell behavior during inhibitor therapy,
i.e., the inhibitor may not achieve the desired outcome due
to the utilization of alternative bypass pathways in certain
tumor cells.
Signal transduction pathways converge on sets of genes
with similar key functions which are regulated by upstream
transcription factors (TFs). TFs occupy short and specific DNA-
sequences denoted as transcription factor binding sites (TFBSs).
TFs and their corresponding TFBSs recruit and regulate the
transcription machinery, thereby governing selective temporal
and spatial activities of their target genes. Moreover, many TFs
play important roles as oncogenes and they are usually activated
downstream in the signaling cascades. Consequently, their
deregulated expression, aberrant activation as well as mutations
contribute to tumorigenesis. For example, the TP53 gene which
encodes an important transcription factor with tumor suppressor
function in cancer, is known to be the most commonly mutated
gene in human cancer (Kandoth et al., 2013). Unsurprisingly,
TFs are central to cancer and became highly desirable points
of interference in cancer gene therapy (Libermann and Zerbini,
2006). In this regard, three major transcription factor families
have been considered highly desirable drug targets: (i) the NF-
κB and AP-1 families of TFs; (ii) the STAT family members; (iii)
the steroid receptors (Libermann and Zerbini, 2006). Although
other additional TF families have been implicated in cancer
to this day, there is still no comprehensive library on TFs
and their specific roles in cancer and, particularly, in different
cancer cell types. However, given the tumor heterogeneity and
cancer cell plasticity, it can be expected that many more TFs
will be associated with potentially important roles in oncogenic
pathways of different cancers.
The third most common cancer in the world is colorectal
cancer (CRC) which originates in the epithelial cells of the
gastrointestinal track and shows a high tendency to metastasize
into the liver. CRC is often caused by mutations in two well-
studied signal transduction pathways, namely the Wnt and the
EGFR pathways (Normanno et al., 2006; Polakis, 2012). Mouse
models have been extensively used in cancer studies to directly
monitor the metastatic progression in CRC. The ability to
study primary tumors as well as distant metastatic sites and to
manipulate the spatial and temporal expression levels of certain
single genes have proven the animal model technology to be a
powerful tool in cancer progression research. Such studies have
often made use of APC-deficient mouse models since mutations
in the adenomatous polyposis coli (APC), an important
component of the Wnt signaling pathway, occur in the majority
of human CRC cells (Karim and Huso, 2013). It is estimated that
the canonical Wnt/β-catenin signaling pathway is abnormally
activated in over 90% of CRCs (Cancer Genome Atlas Network,
2012). Briefly, the canonical Wnt pathway revolves around the
intracellular levels of the transcriptional coactivator β-catenin
which forms a complex with TCF/LEF, thereby controlling
the expression of Wnt signaling targets, such as c-Myc and
cyclin D. β-Catenin is degraded by a destruction complex that
includes the tumor suppressor APC and other proteins (Stamos
and Weis, 2013). Loss of APC leads to a constant activation
of WNT signaling, which promotes proliferation of tumor
cells.
The bottleneck in cancer research has always been a lack of
effective tools to comprehensively study the complex networks
of signaling pathways (Kang, 2005; Gupta and Massagué, 2006).
Therefore, cancer research has largely taken advantage of the
integration of animal models and bioinformatic approaches.
Microarrays and nowadays RNA-sequencing techniques (RNA-
Seq) are used to infer reliable gene regulatory networks based
on the level of all expressed transcripts (transcriptome) (Schena
et al., 1995; Mortazavi et al., 2008). The result of a transcriptome
profiling experiment can be summarized in a set of expressed
genes or transcription units that are meaningful for a certain
experimental condition, disease state or developmental process.
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These technologies have led to paradigm-shifting advances
in cancer research. For example, gene expression profiles in
combination with supervised clustering approaches were used in
breast cancer studies which successfully discriminated between
cancer patients with good prognosis from those with poor
prognosis, thereby leading to the identification of prognostic
cancer genes (van ’t Veer et al., 2002; Weigelt et al., 2005).
However, solely using genomic profiling of tumor samples only
identifies individual genes of a set of signature genes, but does not
provide a functional context for these genes, which is important
for a mechanistic understanding of cancer-associated processes.
Pathway analyses have therefore emerged as powerful tools by
benefiting from the statistical power of entire gene sets using
the overrepresentation in biologically defined pathways rather
than interpreting meaningful functions based on the expression
of individual genes.
Despite the presence of a variety of different approaches
and rich literature on cancer research as mentioned above, to
date, there is still need for comprehensive analyses to detect
key regulators in different colorectal cancer cell lines. In this
study, we made use of distinct murine cancer cell lines and
system biology approaches to identify signature genes and
pathways whose activation may specifically affect invasive tumor
growth. In addition, we exhaustively covered a broad range
of potentially important signaling pathways and focus our
discussion selectively on the study of the roles of various classical
and novel signaling pathways in CRC. Moreover, we aimed to
highlight the meaning of specific TFs in the context of these
pathways on the basis of enriched TFBSs in the promoter regions
of the signature genes. We provide a comprehensive library on
CRC-specific TFs and exemplarily discuss their roles in both CRC
cell lines. Taken together, we identified potential discriminators
between the two CRC cell lines as well as points of interference
for targeted cancer therapy, thus providing further insights into
the complexity of cancer.
2. MATERIALS AND METHODS
2.1. Colorectal Cancer Cell Lines
The CMT-93 cell line, a mouse colorectal polyploid carcinoma
cell line, was purchased from the American Type Culture
Collection, Manassas, USA (CCL223) and was cultured in
DMEM High Glucose Medium (Gibco, Darmstadt, Germany)
supplemented with 10% heat inactivated fetal bovine serum
(FCS; Sigma, Munich, Germany). The murine colorectal cancer
cell line 1638N-T1, derived from Apc1638N adenomas, was
kindly provided by Ron Smits (Smits et al., 1997). Remarkably,
this cell line harbors a targeted mutation at codon 1638 of
the Apc gene, Apc1638T, leading to a truncated Apc protein
(Smits et al., 1999). These were cultured in DMEM High
Glucose Medium supplemented with 15% not heat inactivated
FCS and Insulin/Transferrin/Selenium Solution (Gibco). In
contrast to Smits et al., these cells were not cultured on any
fibronectin/collagen/albumin-coated plates and were passaged
using 0.05% (w/v) trypsin (Biochrom, Berlin, Germany), as long
as they did not show any differences in their morphology,
viability and proliferation.
2.2. RNA Isolation and Sequencing
Total RNA was isolated using the TRIzol Reagent (Invitrogen,
Karlsruhe, Germany) including a DNase I (Roche, Mannheim,
Germany) digestion. RNA integrity and quantity was assessed
with the Agilent Bioanalyzer 2100 and the NanoDrop DD-1000
UV vis spectrophotometer version 3.2.1. 2 µg of total RNA were
used as start material for library preparation (TruSeq Stranded
mRNA Sample Prep Kit from Illumina, Cat NRS-122-2101).
Accurate quantitation of cDNA libraries was performed by using
the QuantiFluor dsDNA System (Promega). The size range of
cDNA libraries was determined applying the DNA 1000 chip
on the Bioanalyzer 2100 from Agilent (280 bp). cDNA libraries
were amplified and sequenced by using the cBot and HiSeq
2000 from Illumina (SR, 1 × 51 bp, 8–9 Gb > 40 M reads
per sample). Sequence images were transformed with Illumina
software BaseCaller to bcl-files, which were demultiplexed to
FASTQ files with CASAVA (version 1.8.2). Quality check was
done via FastQC (version 0.10.1, Babraham Bioinformatics).
2.3. Signature Gene Selection
We started our analyses based on 43433 gene annotations from
Ensembl (mouse assembly GRCm38.p4), which were retrieved
fromRNA-seq samples (Section 2.2; three biological replicates for
each cell line; GSE78696). Based on these samples, we obtained
signature genes as follows:
Using the Trinity platform (Grabherr et al., 2011), we firstly
performed a differentially expressed gene (DEG) analysis based
on both cell lines. After that, employing the Trinity platform
these DEGs were clustered into three main categories using a p-
value cutoff for FDR of 0.05 and the default fold change (default:
2 (meaning 22 or 4-fold)): (i) genes which are most significantly
upregulated in 1638N-T1 (Supplementary Table S1) and, at the
same time, downregulated in CMT-93; (ii) genes which are most
significantly upregulated in CMT-93 (Supplementary Table S2)
and, at the same time, downregulated in 1638N-T1; (iii) the
remaining DEGs which did not fall in the first and second
category. In our further analysis, we only considered genes as
signature genes which fell into the first or second category.
2.4. Data Processing
For the subsequent analyses we used the geneXplain platform
(http://genexplain-platform.com/bioumlweb/), which includes
the TRANSFAC and TRANSPATH databases. We used the
suggested parameters from this platform if not explicitly stated
otherwise.
2.4.1. Enrichment of TFBSs in Promoter Sequences
We applied a conventional enrichment analysis to the previously
identified signature gene sets in order to retrieve specific TFs
whose binding sites or sequence motifs are particularly enriched
in their genomic regions. For the enrichment analysis, we firstly
extracted for each signature gene the corresponding promoter
sequence covering the −1000 to 100 bp regions relative to
transcription start sites. Second, we used position weightmatrices
(PWMs) from the TRANSFAC database (Wingender, 2008) to
predict potential TFBSs in promoters. However, computational
TFBS predictions are generally considered as being flooded
with high rates of false predictions. The accurate prediction of
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TFBSs is still a challenging task. To minimize the rate of false
predictions in our analysis, we collected a specific PWM library
using literature on CRC (Supplementary Table S3). This library
contains 229 colorectal cancer-related non-redundant matrices.
In our further analysis, this library was used with the minFP
profile (cut-offs minimizing false positive rate) that contains the
adjusted thresholds for each PWM to minimize the prediction
of false positive TFBSs. Using our library, we then employed
the F-MATCH program described in Schmid et al. (2006) to
determine the enriched TFBSs in promoters of the signature
genes (foreground set) in comparison to a background set which
contains genes with very small fold changes (∼ 0) in both
cell lines under study. For this purpose, F-MATCH program
applies an iterative process where the initial thresholds in minFP
profile are regularly altered until the best possible thresholds are
defined which provide most significantly enriched TFBSs. This
enrichment analysis yields important key TFs, which may not be
mutated themselves, but their altered activation may potentially
lead to a persistent expression of their target signature genes,
thereby affecting tumorigenesis.
2.4.2. Overrepresented Pathways in Colorectal
Cancer
To gain more insights into the functional properties of
the signature genes and their transcriptional regulators in
CRC, we investigated the overrepresented pathways. For this
purpose, we observed the signal transduction and metabolic
pathways from TRANSPATH (Krull et al., 2006) database which
contains information about genes/molecules and reactions to
build complete networks. In this study, we performed two
distinct pathway analyses, of which the first one refers to the
overrepresented pathways in the signature genes, and the second
one is based on the enriched TFBSs found in the promoters of
these signature genes.
2.4.3. Identification of Master Regulators with
TRANSPATH
Master regulators (MRs) are molecules which are at the very
top of regulatory hierarchy and, thus, they are not affected by
any of their downstreammolecules. Their identification provides
important knowledge to display functional relationships of genes.
In this study, using the TRANSPATH database, we employed a
standard workflow with a maximum radius of 10 steps upstream
of TFs to identify their potential MRs.
2.4.4. Transformation of PWMs to Their
Corresponding TFs and TF Family/Subfamily
Classifications
Multiple PWMs can be assigned to a TF and several TFs belong
to a TF family/subfamily. To obtain the correct assignments
of the PWMs to their respective TFs and TF family/subfamily,
we used the annotations integrated in the geneXplain platform.
TF family/subfamily classifications are curated in TFClass
(http://tfclass.bioinf.med.uni-goettingen.de/tfclass) which is a
classification resource with the aim to catalog TFs based on
their DNA-binding characteristics (Wingender et al., 2013).
TFClass incorporates a six level classification schema which
consists of superclasses, classes, families, subfamilies, genera
and factor species of which subfamilies and factor species are
optional. At the family level, TFs are primarily grouped on
basis of sequence similarities of their DNA-binding domains.
The optional subfamily level comprises two more levels which
represent genes and gene products, termed genera and species,
respectively. TFClass uses a digit-based classification schema
which is analogous to the Enzyme Commission numbering
system. The schema assigns a four-digit number for the top four
classification levels or a six-digit number with respect to the two
optional sublevels of the subfamily level.
3. RESULTS
Classical discovery of individual markers usually involves the
comparison of normal cells vs. cancer cells, which provides
candidates for prognosis as well as individualized treatments.
In this study, however, we focused on the in silico comparative
analysis of two distinct cancer cell lines which serve as models to
describe pathways. The cancer cell-intrinsic pathway repertoire
and their activation status may differ between distinct cancer cell
lines of the same cancer type, which in turn may have an impact
on invasiveness and organ colonization in vivo. Apart from that,
it still remains largely unclear as to what extent these processes
are promoted or inhibited by the tumor microenvironment.
Therefore, it is mandatory to first learn about the cancer cell line-
specific pathway repertoire and, further, to test their functional
consequences in in vivo models. Above all, the cell lines under
study represent suitable models to investigate the molecular
mechanisms by which mutations cause predisposition to the
formation of multiple colorectal tumors. In addition, they can
be used to screen for early disease biomarkers, and to develop
therapeutic and preventive strategies.
3.1. Overview of the Analysis Workflow
Our workflow involved four major steps of which the first one
was performed using the Trinity platform and all following
steps using the geneXplain platform as described below (see also
Figure 1):
1. Selection of signature genes (Section 3.2)
a) Analysis of differentially expressed transcripts
b) Clustering of the most differentially expressed transcripts
2. Identification of overrepresented TRANSPATH pathways
based on signature genes (Section 3.3)
a) Pathway analysis for 1638N-T1 (Section 3.3.1)
b) Pathway analysis for CMT-93 (Section 3.3.2)
3. Identification of transcription factors (TFs) based on signature
genes (Section 3.4)
a) Prediction of enriched TFBSs in promoters using a CRC-
specific PWM library
b) Mapping of TFBSs to corresponding TFs as well as TF
family/subfamily classifications
c) Grouping of TFs as well as TF family/subfamily into
three subsets: 1638NT-1- andCMT-93-intersection-specific
TF set; 1638NT-1-specific TF set; CMT-93-specific TF set
(Sections 3.4.1, 3.4.3, and 3.4.5)
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FIGURE 1 | Workflow for the study of distinct colorectal cancer cell lines. A multi-step workflow is outlined for the comparison of the 1638N-T1 and CMT-93.
(A) The analysis begins with the identification of signature genes based on RNA-seq samples using the Trinity platform. This step generates two disjunct lists of
signature genes which are further applied to different geneXplain analyses. (B) The signature genes are searched for overrepresented TRANSPATH pathways.
Enriched transcription factor binding sites (TFBSs) are searched within the −1 kb/+100 bp promoter regions of the signature genes to obtain transcription factors
(TFs). (C) The TFs are then searched for overrepresented TRANSPATH pathways. (D) A master regulatory network is generated by searching for a master regulator
(red node) up to 10 steps upstream of the TFs (blue nodes) in TRANSPATH. The master regulator is connected via intermediate molecules (green nodes) with the TFs.
d) Identification of overrepresented TRANSPATH pathways
based on the three TF sets (Sections 3.4.2, 3.4.4, and 3.4.6)
4. Identification of upstream master regulators in pathways
based on the three TF sets (Section 3.5)
a) Search for master regulators upstream of TRANSPATH-
mapped molecules of each TF set (Sections 3.5.1, 3.5.2, and
3.5.3)
b) Merging of master regulator pathways based on the top
threemaster regulators found for each TF set (Figures 2–4).
3.2. Signature Genes
Tumor initiation, promotion and progression is generally driven
by genes whose expression is changed in tumor cells. Comparing
gene expression profiles and detection of differentially expressed
transcripts between different cancer cell lines can reveal
molecular characteristics of the tumor cells under study. Using
the Trinity platform we identified signature genes based on their
altered transcriptional regulation in the context of CRC. In total,
2296 and 2342 Ensembl gene IDs were identified for 1638N-T1
and CMT-93, respectively. Supplementary Tables S1, S2 provide
the full sets of signature genes for 1638N-T1 and CMT-93,
respectively.
3.3. Pathway Analyses Based on Signature
Gene Sets
The molecular characterization of tumor cells and the molecular
mechanisms through which tumor cells acquire the capability
to grow progressively, survive and metastasize are numerous
and depend on genetic and environmental factors. On the other
hand, tumor antigens can be recognized by host T cells, thereby
triggering an immune response against the colonization of tumor
cells. It is partly the activation of immune system suppressive
pathways by the tumor cells which can decide whether cancer
evades the anti-tumor immune responses and progresses.
Moreover, the expression of various cytokines and chemokines
controls the balance between anti-tumor immunity and pro-
tumor inflammation. Besides cytokines and chemokines, several
TFs and enzymes play critical roles in regulatory functions during
tumor development. Therefore, analyzing the tumor-specific
expression profiles and detection of these molecules, in particular
TFs, are crucial steps in studying the molecular characteristics
of tumor cells. Moreover, the knowledge about these molecules
and their pathways will provide further information on
the molecular mechanisms which may be linked to tumor
aggressiveness. In this light, we searched for important pathways
for 1638N-T1 and CMT-93 based on their signature genes and
exemplarily provided references for their roles in cancer. With
the previously defined signature gene sets at hand, we obtained
overrepresented TRANSPATH pathways using the geneXplain
platform.
3.3.1. Pathway Analysis for 1638N-T1
In total, 30 TRANSPATH pathways were found to be significantly
overrepresented based on the signature genes of 1638N-T1
(Table 1). The top four most overrepresented pathways indicated
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FIGURE 2 | Master regulatory network based on the intersection-specific TF set. The color coding red, blue and green represent nodes for master regulators,
regulated transcription factors and connecting molecules, respectively.
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FIGURE 3 | Master regulatory network based on the 1638NT-1-specific TF set. The color coding red, blue and green represent nodes for master regulators,
regulated transcription factors and connecting molecules, respectively.
a role for the signature genes Ugt1a1, Ugt1a2, Ugt1a6a, and
Ugt1a7c which encode UDP-glucuronosyltransferases (UGTs).
These detoxification enzymes are involved in the metabolism
of endogenous and xenobiotic compounds (Cooley et al.,
1982; Magnanti et al., 2000). Expression of UGTs has been
implicated in human urinary bladder and colon cancer (Giuliani
et al., 2005; Wang et al., 2012). Furthermore, the first
two of the four pathways related to a mechanism for the
detoxification of NNAL (the metabolized isoform of NNK)
via UGTs-catalyzed glucuronidation pathways (Wiener et al.,
2004). NNK is a tobacco agent widely known for promoting
tumorigenesis and metastasis through its pro-inflammatory
effects (Takahashi et al., 2010). The remaining two pathways
related to glucuronidation pathways which are involved in heme
degradation in response to oxidative stress. Heme ingestion
leads to hyperproliferation and activation of oncogenes as well
as the inhibition of the tumor suppressor p53 in response
to increased cytotoxicity in the mouse colon (Ijssennagger
et al., 2013). The fifth topmost overrepresented pathway
corresponded to the activation of Ras-related protein Rap-1A
(Rap1A) via interferon gamma (IFNγ ). Rap1A is a tumor
suppressor which mediates growth inhibitory responses in
cancer (Alsayed et al., 2000). The cytokine IFNγ plays an
important role in innate and adaptive immune responses and
prevents development of primary and transplanted tumors
(Ikeda et al., 2002). Further, the pathway analysis found two
putative pro-inflammatory metabolic pathways which involve
the molecules eicosanoid hepoxilin A3 (hepA3) and platelet
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FIGURE 4 | Master regulatory network based on the CMT-93-specific TF set. The color coding red, blue and green represent nodes for master regulators,
regulated transcription factors and connecting molecules, respectively.
activating factor (PAF), respectively. Both molecules have been
suggested to play key roles in inflammation-associated cancer
(Mrsny et al., 2004; Tsoupras et al., 2009). Furthermore,
the results reported a signaling cascade which leads to the
activation of mitogen-activated protein kinase 1 (Mapk1/Erk2)
via interleukin-8 (IL-8). Several studies have implicated IL-8 in
tumor angiogenesis, growth, and metastasis in colon, gastric
and pancreatic carcinoma (Li et al., 2001, 2008; Kuai et al.,
2012; Sun et al., 2014a). A recent study showed that IL-8
increases the migration in human CRC cells through the integrin
alpha-V/beta-6 and chemokine receptors CXCR1/2 involving the
activation of Mapk1 and Ets-1 signaling pathway (Sun et al.,
2014a). Another reported pathway relates to the interleukin-
3 (IL-3)-induced activation of the JAK2/STAT5 pathway. IL-3
expression via the T cell receptor signaling pathway is known
to regulate growth and differentiation of hematopoietic stem
cells, neutrophils, eosinophils, megakaryocytes, macrophages,
lymphoid and erythroid cells (Reddy et al., 2000). Lastly, the
results showed overrepresentation for the activation of Wnt
signaling which is aberrantly activated in the majority of CRCs
(Cancer Genome Atlas Network, 2012).
3.3.2. Pathway Analysis for CMT-93
The pathway analysis resulted in the identification of 28
overrepresented TRANSPATH pathways based on the signature
genes of CMT-93 (Table 2). The four topmost overrepresented
pathways share 13/14 hit signature genes which are all associated
with the assembly of protein complexes called adherens junctions
that occur in epithelial and endothelial tissues (Guo et al.,
2007). One prominent signature gene amongst these hits was
E-cadherin (cadherin-1/CDH1) that belongs to the cadherin
superfamily and encodes a calcium-dependent cell adhesion
protein. E-cadherin acts as an invasion suppressor and its loss
in epithelial carcinomas permits the invasion of adjacent normal
tissues. Several studies showed that the level of E-cadherin
expression is inversely correlated with tumor malignancy
(Vleminckx et al., 1991; Cowin et al., 2005; Junghans et al., 2005).
Likewise, protein-protein interactions between E-cadherin and
β-catenin result in the formation of a tumor-suppressor system
(Müller et al., 1999). The regulation of β-catenin/E-cadherin has
been associated with the induction of epithelial-mesenchymal
transition (EMT) and metastasis (Morali et al., 2001; Kim et al.,
2002; Eger et al., 2004).
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TABLE 1 | Overrepresented TRANSPATH pathways for the signature genes of 1638NT-1.
Pathway Hit names of signature genes P-value
detoxification and bioactivation of tobacco-derived
carcinogen NNK
Cbr3, Ugt1a1, Ugt1a2, Ugt1a6a, Ugt1a7c 4.755E-4
NNK→ NNAL-O-glucuronide, NNAL-N-glucuronide Cbr3, Ugt1a1, Ugt1a2, Ugt1a6a, Ugt1a7c 4.755E-4
heme, globin→ bilirubin beta-diglucuronide Ugt1a1, Ugt1a2, Ugt1a6a, Ugt1a7c 0.00326
hemoglobin oxidation Ugt1a1, Ugt1a2, Ugt1a6a, Ugt1a7c 0.00326
IFNgamma→ Rap1 Cybb, Hspa1a, Ifngr1, Ncf4 0.01253
Syk→ RhoA Syk, Vav2 0.01349
Hck→ RhoA Hck, Vav2 0.01349
hepoxilin A3→ Hepoxillin A3-D Ggt7, Tgm2 0.01349
G-alpha-q→ IP3 Cybb, Ncf4, Plcb1 0.01385
BCR→ p38 C3,Cybb, Ncf4, Syk 0.01618
BCR —MLK3→ c-Jun C3, Cybb, Ncf4, Syk 0.01618
catabolism of PAF Enpp2, Pla2g7, Plcb1, Plcg2 0.01618
alpha IIb beta3→ Rac1 Cybb, Fyb, Ncf4, Prkg1, Syk 0.0211
alpha IIb beta3 pathway Cybb, Fyb, Ncf4, Prkg1, Syk 0.0211
IL-8→ ERK2 Cxcl1, Cybb, Gnai1, Il8, Ncf4 0.02495
WAVE2→ Arp2/3 complex Acta1, Actr3b, Cybb, Cyfip2, Ncf4 0.02495
Epo→ Syk Epor, Syk 0.02577
PMCA4 —/ nNOS Dmd, Snta1 0.02577
Wnt activation of LRP5/6/frizzled/axin complex Fzd4, Fzd8, Wnt1 0.0268
SDF-1→ G-protein Cxcr4, Cybb, Gnai1, Ncf4, Pik3r5 0.02923
BCR→ cytoskeletal reorganization C3, Cybb, Ncf4, Syk 0.03089
BCR→ c-Jun C3, Cybb, Ncf4, Syk 0.03089
SLP-65 —/ Raf-1 Cybb, Ncf4, Plcg2 0.03503
dehydroepiandrosterone→ estriol 16-glucuronide Cyp1b1, Cyp4a12a, Cyp4b1, Ugt1a1, Ugt1a2, Ugt1a6a, Ugt1a7c 0.03888
IL-3→ STAT5 Csf2rb, Il3ra 0.04102
beta-glucan —DECTIN1→ IP3, DAG Plcg2, Syk 0.04102
metabolism of estrogens Cyp1b1, Cyp4a12a, Cyp4b1, Ugt1a1, Ugt1a2, Ugt1a6a, Ugt1a7c 0.04299
Rac1 —p65PAK→ Arp2/3 complex Acta1, Actr3b, Cybb, Ncf4 0.04396
Src→ Rac1 Cybb, Ncf4, Vav2 0.0444
N-cadherin —Eplin→ actin Acta1, Cdh2, Ctnna2 0.0444
The results included further pathways which are related to
the phosphorylation and desphosphorylation of the β-catenin/E-
cadherin complex. In this regard, it has been reported that
phosphorylation of β-catenin, e.g., through the epidermal growth
factor receptor (EGFR) or the tyrosine-protein kinase Src,
leads to the dissociation of the complex and consequently
to the accumulation of free β-catenin. On the contrary,
dephosphorylation of β-catenin results in the formation of the
complex (Müller et al., 1999). Another overrepresented pathway
corresponded to nerve growth factor (NGF) signaling via the
tyrosine kinase receptor TrkA. NGF has been associated with
cancer cell proliferation as well as apoptosis of colon cancer
cells (Molloy et al., 2011; Anagnostopoulou et al., 2013) and
with angiogenesis (Romon et al., 2010). Further overrepresented
pathways related to the angiopoietin-Tie signaling system which
plays a role in the regulation of angiogenesis (Fagiani and
Christofori, 2013). In tumors, angiopoietin-2 (Ang2) inhibits the
activity of the receptor tyrosine kinase Tie2 and destabilizes blood
vessels, thereby facilitating angiogenesis (Holash et al., 1999a,b;
Augustin et al., 2009). Moreover, several other overrepresented
pathways could be linked to anti-tumor properties. These
included two p53-dependent pathways which lead to the
induction of the cyclin-dependent kinase inhibitor 1 (p21Cip1) or
the p53 upregulatedmodulator of apoptosis (Puma), respectively.
Downregulation of p21Cip1 expression has been associated with
poor prognosis and expression of Puma with a rapid apoptosis in
CRC (Pasz-Walczak et al., 2001; Yu et al., 2001). Furthermore, the
results also included overrepresented pathways which related to
vitamin D receptor (VDR) signaling and vitamin D metabolism.
VDR signaling is activated upon binding of vitamin D and plays
a role in cancer progression as well as cross-talks with multiple
other pathways (Slattery, 2007). For example, several studies
have suggested interactions of vitamin D or its active vitamin
D metabolite, calcitriol, with β-catenin (Deeb et al., 2007; Zheng
et al., 2012; Klampfer, 2014). These interactions represent points
of convergence between VDR and canonical Wnt signaling in
CRC, which has been linked to inhibition of Wnt signaling,
tumor growth inhibition, the activation of apoptotic pathways,
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TABLE 2 | Overrepresented TRANSPATH pathways for the signature genes of CMT-93.
Pathway Hit names of signature genes P-value
beta-catenin:E-cadherin complex phosphorylation and dissociation Axl, Blk, Cdh1, Epha1, Erbb3, Fes, Kit, Lck, Mertk, Ntrk1, Ret, Tek, Txk 0.00147
beta-catenin:E-cadherin complex phosphorylation and dephosphorylation Axl, Blk, Cdh1, Epha1, Erbb3, Fes, Kit, Lck, Mertk, Ntrk1, Ret, Tek, Txk 0.00147
tyrosine dephosphorylation of plakoglobin Axl, Blk, Cdh1, Epha1, Erbb3, Fes, Kit, Lck, Mertk, Ntrk1, Ret, Tek, Txk 0.00166
beta-catenin network Axl, Blk, Cdh1, Epha1, Erbb3, Fes, Kit, Lck, Magi2, Mertk, Ntrk1, Ret, Tek,
Txk
0.002
NGF —p75NTR→ trkA Ngf, Ntrk1 0.00464
VDR network Cyp27a1, Cyp2r1, Hist1h4i, Hist1h4j, Hist2h3c2, Hist2h4, Hist4h4, Vdr 0.00541
NGF→ trkA Ngf, Ntrk1 0.0133
Tie2 dephosphorylation Ptprb,Tek 0.0133
CO2, H2O→ spermine Arg1, Car14, Car2, Car3, Car6 0.01419
Angiopoietin/Tie signaling Dok2, Nos3, Ptprb, Sfn, Tek 0.01419
creatine biosynthesis and degradation Car14, Car2, Car3, Car6, Gatm, Mat1a 0.01625
VDR→ RXR-alpha→ transcriptional activation Hist1h4i, Hist1h4j, Hist2h3c2, Hist2h4, Hist4h4, Vdr 0.01891
sphinganine→ ceramide-2,3,6,7 Cers1, Cers4, Ugcg 0.01936
urea and aspartate cycles, polyamine and creatine synthesis Arg1, Car14, Car2, Car3, Car6, Gatm 0.02184
CO2, L-ornithine→ L-arginine Car14, Car2, Car3, Car6 0.02475
p53→ p21Cip1 Hist1h4i, Hist1h4j, Hist2h4, Hist4h4 0.02475
p53→ PUMA Hist1h4i, Hist1h4j, Hist2h4, Hist4h4 0.02475
7-dehydrocholesterol→ calcitriol Cyp27a1, Cyp2r1 0.02542
formation of vitamin D3 and 1alpha,25-dihydroxycholecalciferol Cyp27a1, Cyp2r1 0.02542
Nedd4→ trkA Ngf, Ntrk1 0.02542
PKAc→ NR2C Grin1, Prkaca 0.02542
NR2A:NR2B —PKAc→ Ca Grin1, Prkaca 0.02542
Vitamin D metabolism Cyp27a1, Cyp2r1 0.02542
Tie2 —p56Dok-2→ PAK1 Dok2, Tek 0.02542
L-tryptophan→ 5-hydroxyindoleacetate Aldh1a7, Maoa, Tph1 0.03438
degradation of tryptophan Acmsd, Aldh1a7, Maoa, Tph1 0.03625
Csk, CD45→ Lck Lck, Ptprc 0.04048
NR2B:NR2C —CaMKII→ c-Fos Camk2d, Grin1, Prkaca 0.0436
inhibition of angiogenesis and inhibition of tumor-promoting
inflammation (Deeb et al., 2007; Zheng et al., 2012; Klampfer,
2014).
3.4. Promoter Analysis Based on Signature
Genes
Altered gene expression is generally a result of the dysregulated
activity of TFs that may play central roles as oncogenes and
tumor suppressors. These proteins are often potential targets for
cancer therapies due to the fact that many oncogenic signaling
pathways involve TFs whose aberrant activation and inactivation
contributes to tumor development and progression.We applied a
promoter analysis to the previously identified signature genes in
order to display which TFs are potentially important regulators
in the cell lines under study. This analysis was performed
using geneXplain which quantifies the enrichment of TFBSs in
promoter regions of the signature genes. In total, 135 and 117
TFs were identified for 1638N-T1 and CMT-93, respectively.
These numbers include 51 (Supplementary Table S4) and
33 TFs (Supplementary Table S5) that were exclusively
enriched in 1638N-T1 or CMT-93, respectively, as well as 84
overlapping TFs in the intersection between both cell lines
(Supplementary Table S6). We exemplarily highlighted several
TF families/subfamilies which are present for the three TF
sets. In a subsequent analysis, we additionally searched for
overrepresented pathways on the basis of these sets.
3.4.1. Intersection-Specific TF Families/Subfamilies
of 1638N-T1 and CMT-93
The enriched TFBSs were classified into 32 prominent TF
families/subfamilies according to TFClass (Table 3). Our analysis
detected several members of the SMAD factor family that were
found to have enriched binding sites in the promoters. These
factors are a major component of TGF-β signaling which is
involved in the regulation of cell growth in the normal intestinal
epithelium. Alterations in their expression contribute to cancer
aggressiveness in CRC (Xie et al., 2003; Xu and Pasche, 2007;
Korchynskyi et al., 1999; Fleming et al., 2013). Furthermore,
the analysis revealed overrepresentation for members of the
Jun-related factors and Fos-related factors. The protein AP-
1 is composed of either Jun-Jun homodimers or Jun-Fos
heterodimers and plays a role in differentiation, proliferation,
and apoptosis (Ameyar et al., 2003). AP-1 is induced by c-Jun
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TABLE 3 | Intersection-specific TF families/subfamilies between 1638N-T1
and CMT-93.
TF classification TF family/subfamily
1.1.1 Jun-related factors
1.1.1.1 Jun factors
1.1.1.2 NF-E2-like factors
1.1.2 Fos-related factors
1.1.2.1 Fos factors
1.1.3 Maf-related factors
1.1.3.1 Large Maf factors
1.1.3.2 Small Maf factors
1.1.8 C/EBP-related
1.1.8.1 C/EBP
1.2.1 E2A-related factors
1.2.2 MyoD / ASC-related factors
1.2.2.1 Myogenic transcription factors
1.2.3.1 Tal / HEN-like factors
1.2.6 bHLH-ZIP factors
1.2.6.1 TFE3-like factors
1.2.6.2 USF factors
1.2.6.5 Myc / Max factors
1.2.6.7 Mad-like factors
2.1.2 Thyroid hormone receptor-related factors (NR1)
2.1.2.4 Vitamin D receptor (NR1I)
2.1.3 RXR-related receptors (NR2)
2.1.3.1 Retinoid X receptors (NR2B)
2.1.3.2 HNF-4 (NR2A)
3.1.10 POU domain factors
3.1.10.2 POU2 (Oct-1/2-like factors)
3.1.4 TALE-type homeo domain factors
3.1.4.4 PBX
6.4.1 Runt-related factors
7.1.1 SMAD factors
7.1.1.1 Regulatory Smads (R-Smad)
7.1.1.3 Repressor-Smads (I-Smad)
N-terminal protein kinases (JNK) and ERK MAPKs pathways
or the canonical Wnt signaling pathway in CRC (Licato et al.,
1997; Mann et al., 1999), thereby affecting CRC cell proliferation
(Suto et al., 2004). Binding site enrichment was also detected
for the CCAAT-enhancer binding protein (C/EBP) family of TFs
whose expression has been associated with invasiveness of human
colorectal cancer (Rask et al., 2000). Likewise, several members
of the POU domain factor family, including Oct-4 (Pou5f1),
were found in the intersection between both cell lines. It has
been reported that Oct-4 promotes metastasis in CRC through
EMT (Dai et al., 2013). Furthermore, Oct-4 knockdown leads to
decreasedWnt pathway activity and high risk for liver metastases
in CRC patients (Dai et al., 2013). Enrichment for binding
sites of VDR, which belongs to the Thyroid hormone receptor-
related factor (NR1) family, was also detected in the intersection.
It has been suggested that vitamin D has no effect on tumor
reduction in APC-deficient mice and that VDR expression is lost
in the majority of the colon cancer cells (Giardina et al., 2015).
Interestingly, the analysis also revealed enrichment for binding
sites of β-catenin which interacts as a cofactor with members
of the TCF-7-related factor family to activate Wnt target gene
expression (see Supplementary Table S6).
3.4.2. Overrepresented TRANSPATH Pathways Based
on Intersection-Specific TFs
Based on the 84 overlapping TFs in the intersection of both
cell lines, the pathway analysis revealed overrepresentation
for 35 TRANSPATH pathways (Table 4). Members of the
SMAD factor family were found to be involved in many of
the top overrepresented pathways. In this context, the TGF-
β pathway was detected among the most overrepresented
pathways. Likewise, SMADs were also found to be involved
in a pathway which corresponded to the regulation of
endothelin-1 (ET-1). ET-1 is a vasoconstrictor peptide, which
is known to be produced by CRC cells and stimulates CRC
proliferation (Asham et al., 2001; Grant et al., 2007; Knowles
et al., 2012). The second most overrepresented pathway
corresponded to the transcriptional regulation of ECM
components. ECM sustains normal tissue homeostasis and
prevents malignant transformation (Gao et al., 2014). Its
anti-tumor properties are opposed by chronic inflammation,
which may lead to the conversion of a tumor-inhibiting
into a tumor-promoting microenvironment (Gao et al.,
2014).
Furthermore, the analysis showed overrepresentation for
a PPAR-related pathway which comprises the peroxisome
proliferator activated receptors PPAR-α, PPAR-γ and Smads.
It was shown that activation of PPAR-γ inhibits TGF-
β-induced loss of E-cadherin expression, the induction of
mesenchymal markers (vimentin, N-cadherin, fibronectin),
MMPs and antagonizes Smad3 function, thereby preventing
metastasis in lung cancer (Reka et al., 2010). This pathway
has also been implicated in the induction of apoptosis as well
as inhibition of cyclooxygenase-2 (COX-2) in CRC (Yang and
Frucht, 2001). Activation of the PPAR pathway was shown to
cause reduction in linear and clonogenic growth and, thus, it
has been suggested that PPAR-γ modulates cell growth and
differentiation of CRC cells (Sarraf et al., 1998). Moreover, it
was shown that PPAR-γ expression is altered in APC-deficient
mice, an effect which is thought to be mediated by the Wnt/β-
catenin pathway (Jansson et al., 2005). In conformity with
the overrepresented pathways, which were found based on the
signature genes of CMT-93, a VDR network-related pathway was
also found based on the intersection-specific TFs.
3.4.3. 1638N-T1-Specific TF Families/Subfamilies
The enriched TFBSs can be classified into 14 prominent
TF families/subfamilies based on the 1638N-T1-specific TFs
(Table 5). Amongst these, the factors Onecut1 and Onecut2,
which belong to the HD-CUT factors family, were found to
be enriched in the signature genes of 1638N-T1. Through
targeting of Onecut2, the microRNA miR-429 has been reported
to regulate the expression of several EMT-related markers (Sun
et al., 2014b). Overall, it has been suggested that Onecut2 is
involved in EMT, migration and invasion of CRC cells (Sun et al.,
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TABLE 4 | Overrepresented TRANSPATH pathways based on the intersection-specific TF set of 1638N-T1 and CMT-93.
Pathway Hit names of TFs P-value
Endothelin-1 gene regulation Fos, Jun, Smad3, Smad4 2.8851480825350153E-8
Transcriptional Regulation of ECM components Smad2, Smad3, Smad4, Tfe3 4.2462045176114295E-7
PPAR pathway Ppara, Pparg, Rxra, Rxrb, Smad2, Smad3 4.401281772213993E-7
BMP7→ Smad1, Smad5, Smad8 Smad1, Smad4, Smad5, Smad9 9.814052909861147E-7
TGFbeta pathway Fos, Jun, Pparg, Smad1, Smad2, Smad3, Smad4, Smad5, Smad7, Smad9,
Tfe3
1.1668767789940478E-6
SMAD7, SIK1 gene induction Smad2, Smad3, Smad4 2.3427402430218484E-6
MIC2 signaling Fosb, Jun, Jund, Srf 8.907929442840803E-6
Smad2/3, PPARgamma, regulation of bioavailability Pparg, Smad2, Smad3 9.284406529601274E-6
MIC2-isoform2 —JNK, JunD→ MMP9 Fosb, Jun, Jund 4.556873521617853E-5
TGFbeta1→ Smad1, Smad2, Smad5 Smad1, Smad2, Smad5 7.900923266022097E-5
MIC2-isoform2 —FosB→ MMP9 Fosb, Jund, Srf 1.2524823045846698E-4
mammalian Hippo network Smad2, Smad3, Smad4, Smad7, Tead1 1.609311066368507E-4
RA, 15d-PGJ2→ RXR-beta, PPAR-gamma Pparg, Rxrb 1.830040551373434E-4
RXR-beta, VDR heterodimerization Rxrb, Vdr 1.830040551373434E-4
Smad2/3 —TAZ→ cytoplasmic retention Smad2, Smad3, Smad4 3.5891749789138236E-4
Sox9 —Smad3→ COL2A1 Smad2, Smad3 5.443266849267895E-4
MyoD regulation Myod1, Tcf3 5.443266849267895E-4
MKK4 —/ PPAR-gamma Pparg, Rxrb 0.0010793689633243411
Ctbp1 —/ Smad3 Smad3, Smad4 0.0010793689633243411
ERK1→ NQO1 Mafk, Nfe2l2 0.0010793689633243411
E2F —/ Smad4 Smad3, Smad4 0.0017836171536470523
Nrf2→ HMOX1 Mafk, Nfe2l2 0.0017836171536470523
stress-associated pathways Jun, Mitf, Myf6, Pparg, Rxra, Rxrb 0.0023269497130444508
PRIC complex→ PPAR-alpha Ppara, Rxra 0.002652641362864685
TGFbeta1→ Smad2/3 Smad2, Smad3 0.002652641362864685
MEK→ EZR Fos, Jun 0.002652641362864685
p38 pathway Jun, Mitf, Myf6, Pparg 0.0034193798154062926
15-Keto-PGE2→ TP63 Pparg, Smad2 0.003682094214938695
TGFbetaR-I —pak2, ERK1→ SMAD7, SERPINE1 Smad2, Smad3, Smad4 0.003904012718560197
15d-PGJ2→ PPAR-gamma Pparg, Rxra 0.009320059910591498
Regulation of mesendoderm differentiation genes Smad2, Smad4 0.012994431232912744
IRAK-1 —MKK3→ TNF Fos, Jun 0.015031819490714783
JNK pathway Jun, Pparg, Rxra, Rxrb 0.016302058148038395
VDR network Rxra, Rxrb, Vdr 0.01758202640044028
TGFbetaR-I→ ERK Smad2, Smad3 0.04188993264127895
2014b). Onecut1 (Hnf6) expression was found to be positively
correlated with the expression of p53 and E-cadherin in human
lung cancer. The Onecut1-mediated induction of p53 is thought
to inhibit EMT, migration and invasion (Yuan et al., 2013).
Moreover, the analysis detected the HOX-related factors Cdx1
and Cdx2, which regulate intestine-specific gene expression and
enterocyte differentiation (Suh et al., 1994; Suh and Traber,
1996; Taylor et al., 1997; Freund et al., 1998; Soubeyran et al.,
1999; Lynch et al., 2003). In addition, it has been suggested that
expression of Cdx1 reduces cancer cell proliferation by reducing
cyclin D1 expression (Lynch et al., 2003). Interestingly, Cdx1 and
Cdx2 also inhibit proliferation of CRC cells by blocking canonical
Wnt signaling activity (Guo et al., 2004). In contrast, another
study indicated that Cdx2 can promote expression of Wnt/β-
catenin pathway genes (da Costa et al., 1999). Furthermore, the
analysis revealed overrepresentation for several members of the
interferon regulatory factor (IRF) family. Most IRFs play central
roles in immune response, apoptosis and are known to exhibit
tumor suppressor properties in cancer (Bouker et al., 2005). For
example, anti-tumor function of IRF-1- and IRF-5-associated
pathways have been suggested in CRC (Hu and Barnes, 2006;
Yuan et al., 2015). The analysis also detected Sox9, a member
of the SOX-related factors. Sox9 is a target as well as potential
upstream regulator of Wnt signaling (Blache et al., 2004; Bastide
et al., 2007).
3.4.4. Overrepresented TRANSPATH Pathways Based
on 1638N-T1-Specific TFs
In total, 7 overrepresented pathways were found based on the
51 exclusive TFs for 1638NT-1 (Table 6). The results included
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TABLE 5 | 1638N-T1-specific TF families/subfamilies.
TF classification TF family/subfamily
3.1.1.9 CDX (Caudal type homeobox)
3.1.9 HD-CUT factors
3.1.9.1 ONECUT
3.1.10.7 HNF1-like factors
3.3.1 Forkhead box (FOX) factors
3.3.1.1 FOXA
3.3.1.6 FOXF
3.5.3 Interferon-regulatory factors
4.1.1 SOX-related factors
4.1.1.3 Sox-related factors, Group C
4.1.1.4 Sox-related factors, Group D
4.1.1.5 Sox-related factors, Group E
6.1.3 NFAT-related factors
8.2.1 HMGA factors
TABLE 6 | Overrepresented TRANSPATH pathways based on the
1638N-T1-specific TF set.
Pathway Hit names P-value
of TFs
dsRNA→ IRF-7:IRF-3:CBP:p300 Irf3, Irf7 3.947146928237511E-4
LPS→ IRF-3:IRF-7:CBP:p300 Irf3, Irf7 0.0014260355781928803
wnt→ beta-catenin Ctnnb1, Tbp 0.005286143325503229
TLR9 pathway Irf1, Irf7 0.0106622039857671
TLR3 pathway Irf3, Irf7 0.01598971078797065
wnt pathway Ctnnb1, Tbp 0.02936961872680831
TLR4 pathway Irf3, Irf7 0.03155510304218106
overrepresented pathways which corresponded to the TLR (Toll-
like receptor) pathways TLR3, TLR4, and TLR9. TLRs are pattern
recognition receptors (PRRs) that play key roles in innate and
adaptive immune responses. In host defence, TLRs recognize
pathogens by pathogen-associated molecular patterns (PAMPs).
TLRs are involved in inflammatory reponses, cell proliferation
and survival, and have been associated with pro-tumor as well
as anti-tumor effects in cancer (Rakoff-Nahoum and Medzhitov,
2009; Basith et al., 2012). TLR signaling pathways promote
the production of cytokines and chemokines via interfering
with intracellular pathways and activation of TFs, such as IRFs
and NF-κB (Li et al., 2014). In particular, activation of the
TLR9 pathway promotes the development of anti-tumor T-cell
responses (Krieg, 2008). In contrast, it was also shown that
this pathway can promote angiogenesis and cancer progression
(Belmont et al., 2014; Holldack, 2014). TLR3 activation mediated
by dsRNA was shown to trigger apoptosis of human breast
cancer cells (Salaun et al., 2006). Additionally, signaling by IRF-
3 has been implicated in TLR3-mediated apoptosis in prostate
cancer (Gambara et al., 2015). Another overrepresented TRL-
related pathway corresponded to the lipopolysaccharide (LPS)-
induced activation of the TFs IRF-3, IRF-7, and CBP/p300 via
the TLR4/MD2 complex. Moreover, it was shown that metastasis
of CRC cells is increased through a signaling cascade involving
TABLE 7 | CMT-93-specific TF families/subfamilies.
TF classification TF family/subfamily
1.1.2 Fos-related factors
1.2.6.3 SREBP factors
2.3.3.1 GLI-like factors
3.5.2 Ets-related factors
3.5.2.1 Ets-like factors
3.5.2.2 Elk-like factors
3.5.2.3 Elf-1-like factors
6.1.1 NF-kappaB-related factors
6.1.5 Early B-Cell Factor-related factors
6.2.1 STAT factors
LPS-induced TLR4 signaling as well as downstream PI3K/Akt
signaling and β1 integrin activity (Hsu et al., 2011). LPS also
increases phosphorylation of Mapk1 and p38, activation of
NF-κB, and promotes cytokine production, such as that of
IL-8, vascular endothelial growth factor (VEGF), and TGF-β in
human colon cells (Tang and Zhu, 2012). Moreover, the same
study has implicated TLR4 in promoting immune escape of
the human colon cancer cells by inducing immunosuppressive
factors and apoptosis resistance (Tang and Zhu, 2012). Strikingly,
two pathways corresponded to the canonical Wnt/β-catenin
signaling pathway which is of high relevance in CRC.
3.4.5. CMT-93-Specific TF Families/Subfamilies
The enriched TFBSs can be classified into 10 prominent TF
families/subfamilies for the CMT-93-specific TFs (Table 7). The
results included Ebf3 which is a member of the Early B-
Cell Factor-related factors family. This family plays a role in
differentiation of specific cell types such as B lymphocytes
and olfactory cells (Zhao et al., 2006). Expression of Ebf3 was
previously shown to promote cell cycle arrest and apoptosis in
several tumor cell lines including colon carcinoma (Zhao et al.,
2006).
The analysis also reported enriched TFBSs for the NF-
κB-related factor family. NF-κB signaling is usually induced
by inflammation and also known to be triggered by cancer
progression. Many recent findings indicate that NF-κB is
constitutively activated in malignant cells of various cancers
including CRC (Nakshatri et al., 1997; Wang et al., 1999;
Lindholm et al., 2000; Lind et al., 2001; Kojima et al., 2004),
thereby promoting, cell proliferation, angiogenesis, metastasis,
upregulation of chemokine secretion and other anti-apoptosis
proteins (Sakamoto et al., 2009; Wang et al., 2009). Furthermore,
enriched binding sites were detected for the signal transducer
and activator of transcription (STAT) family which are critical
regulators of immune and inflammatory responses (Yu et al.,
2009). These factors play an important role in many types of
cancer, including colorectal cancer, as they may promote pro-
tumor inflammatory pathways such as NF-κB and JAK/STAT
pathways, as well as suppress anti-tumor immunity (Wang et al.,
2009; Yu et al., 2009; Slattery et al., 2013). The activation of
Stat3 and Stat5 has been shown to promote cell proliferation
and invasion in cancer (Yu et al., 2009), while Stat3 was also
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found to be persistently activated and overexpressed in colon
cancers (Klampfer, 2008). Our analysis also revealed binding
site enrichment for several members of the family of Ets-related
factors which are involved in diverse cellular processes, thereby
often cooperatively interacting with other TFs and co-factors
(Oikawa, 2004). In cancer, this family is known to regulate
genes which play a role in angiogenesis, invasion and metastasis.
Therefore, their altered expression has been implicated in
development and progression of cancer (Bassuk and Leiden,
1997; Graves and Petersen, 1998; Oikawa and Yamada, 2003;
Oikawa, 2004). Moreover, it has been suggested to use ETS-
related factors as prognostic markers in cytotoxic treatment of
metastatic colorectal cancer (Giessen et al., 2013).
3.4.6. Overrepresented TRANSPATH Pathways Based
on CMT-93-Specific TFs
In total, 52 overrepresented pathways were found based on
the 33 exclusive TFs for CMT-93 (Table 8). Most of these
overrepresented pathways involved NF-κB family members.
Further overrepresented pathways involved the tumor necrosis
factor-alpha (TNF-α) of which one related to the TNF-α-
mediated activation of NFκB. An increase in production
of the pro-inflammatory cytokine TNF-α is linked to poor
outcome in CRC (Balkwill2005, Mantovani2005, Coussens2002,
Balkwill2001). Interestingly, TNF-α was shown to promote Wnt
signaling through translocation of β-catenin into the nucleus in
gastric tumor cells (Oguma et al., 2008).
In conformity with the results obtained for the 1638N-T1-
specific TFs, TLR-related pathways for five different TLRs (TLRs
2,3,4,8,9) were also detected for the TFs of the CMT93-specific
set. The results further included several overrepresented STAT
factors-related pathways that included an activation of STATs
by platelet-derived growth factor (PDGF)-mediated signaling.
Signaling via PDGF tyrosine kinase receptors plays an important
role in angiogenesis, mesenchymal cell migration, proliferation
and the expression and activation of PDGF receptors is
particularly associated with invasion and metastasis in CRC (Yu
et al., 2003; Kitadai et al., 2006; Steller et al., 2013).
Moreover, the analysis detected overrepresentation for LXR-
related pathways that implicate a role for NFκB subunits
RELA/p65, NFKB1/p105, NFKB1/p50 as well as interleukin-1
beta (IL-1β). Interestingly, the signature gene set for CMT-93
included the factors Nr1h2 and Nr1h3, two members of the
thyroid hormone receptor-related factor (NR1) family. These
genes encode liver X receptors (LXRs), of which the oxysterol
receptor LXRα (Nr1h3) is thought to increase caspase-dependent
apoptosis, slow growth of xenograft tumors in CRC mouse
models and may negatively interfere with Wnt signaling through
direct binding to β-catenin in CRC (Uno et al., 2009; Sasso
et al., 2013). Hence, LXRs have been considered important
potential targets in cancer therapeutics on account of their tumor
suppressor activities (Sasso et al., 2013; Vedin et al., 2013; Lin
and Åke Gustafsson, 2015). With respect to IL-1β , this pro-
inflammatory cytokine has been associated with angiogenesis,
invasiveness of different tumor cells and increased risk of CRC
(Voronov et al., 2003; Andersen et al., 2013).
3.5. Identification of Upstream Master
Regulators in Pathways Based on TF Sets
In the previous step, we reported potentially important TFs for
the sets of signature genes, on the basis of which we defined sets
of TFs for the intersection between the two cell lines as well as
for the 1638N-T1-specific and CMT-93-specific TFs. Since signal
transduction pathways can modulate the activity of nuclear TFs,
activation mutations in these pathways can lead to the altered
expression of the TFs and their target genes. These pathways
are diverse in both their complexity and the mechanism of
signal transduction, and even more complexity is added through
cross-talks or transactivation signals between different pathways.
Therefore, we were interested in the detection of upstream
regulators, called master regulators, for the previously defined TF
sets. We additionally aimed to construct the upstream pathways
which may regulate activity or inhibition of the TFs.
We applied the master regulator analysis from geneXplain
to each of the three TF sets, namely the intersection with
overlapping TFs between 1638N-T1 and CMT-93, the 1638N-
T1-specific and the CMT-93-specific TFs. This workflow will
first map the set-specific TFs to TRANSPATH molecules and
then search based on the TRANSPATH knowledge for upstream
master regulators. We report the top three master regulators for
each TF set (Table 9) and provide references for their roles in
cancer. Noteworthy, we only proposed distinct master regulators
for each gene set, i.e., different splice variants or isoforms of a
master regulator reported by the analysis were counted as the
same master regulator.
The master regulators and their pathways, denoted as master
regulator pathways, constitute the set-specific TFs which are
either connected to other set-specific TFs or intermediate
molecules. These intermediate molecules are not contained
within the respective TF sets but function as a bridge between
the set-specific TFs and the master regulator(s) in the pathways.
Since the pathways of the top ranked master regulators share
many of the interacting nodes and, thus, are very similar to each
other, we merged the top 3master regulator pathways for each set
into one network.
3.5.1. Prediction of Master Regulators and
Construction of a Master Regulatory Network Based
on the Intersection-Specific TF Set
For the intersection-specific TF set, we obtained the three
master regulators Rad23A, Smad3, and Melk that reach 91, 74,
and 93 TFs from the set, respectively. The master regulator
Rad23A is involved in DNA damage recognition and nucleotide-
excision repair. A recent study has implicated Rad23A in nuclear
translocation of the apoptosis-inducing factor (AIF) during
induction of cell death (Sudhakar and Chow, 2014). However, not
much is known about its specific function in CRC.
As a major component of the TGF-β signaling pathway, the
Smad3 master regulator plays a pivotal role in survival, invasion,
and metastasis of CRC cells (Xu and Pasche, 2007; Fleming et al.,
2013). However, despite the fact that not much is known about
the pathogenic role of Smad3, mutations in the gene occur rather
rarely in human CRC (Ku et al., 2007). Loss of Smad3 has been
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TABLE 8 | Overrepresented TRANSPATH pathways based on the CMT-93-specific TF set.
Pathway Hit names of TFs P-value
PDGF B→ STATs Stat3, Stat5a, Stat5b 6.272149884041184E-7
STAT5→ Ccnd1 Stat5a, Stat5b 3.1953088992325076E-5
STAT5→ CISH Stat5a, Stat5b 3.1953088992325076E-5
STAT5→ CSN2 Stat5a, Stat5b 3.1953088992325076E-5
PDGF B→ STAT1alpha, STAT5 Stat5a, Stat5b 9.554461322021479E-5
importin-alpha3→ NFkappaB Nfkb1, Rela 9.554461322021479E-5
Pin1→ p50:RelA-p65 Nfkb1, Rela 9.554461322021479E-5
Epo —Jak2→ STAT5 Stat5a, Stat5b 1.9046201145220444E-4
Epo→ STAT5 Stat5a, Stat5b 1.9046201145220444E-4
IL-3→ STAT5 Stat5a, Stat5b 3.1639480397985514E-4
LXR —/ IL1B Nfkb1, Rela 3.1639480397985514E-4
SOCS-1→ p50:RelA-p65 Nfkb1, Rela 4.730345816689199E-4
TLR8 —Btk→ NF-kappaB Nfkb1, Rela 4.730345816689199E-4
TLR9 —Btk→NF-kappaB Nfkb1, Rela 4.730345816689199E-4
p50:RelA-p65→ SELE Nfkb1, Rela 4.730345816689199E-4
IFNalpha/beta pathway Stat3, Stat5a, Stat5b 6.440779144960161E-4
fMLP→ NFkappaB Nfkb1, Rela 6.600749950470129E-4
IL-2→ STAT5 Stat5a, Stat5b 6.600749950470129E-4
IFNalpha, IFNbeta→ STAT5 Stat5a, Stat5b 6.600749950470129E-4
LXR network Nfkb1, Rela 6.600749950470129E-4
IL-2 - STAT5 pathway Stat5a, Stat5b 8.772117434506635E-4
cPKC —CARD9→TRAF6 Nfkb1, Rela 8.772117434506635E-4
mannan, Dectin2 Nfkb1, Rela 8.772117434506635E-4
EDA-A2 —TRAF3→ p50:RelA-p65 Nfkb1, Rela 0.0011241425642107344
EDA-A1→ p50:RelA-p65 Nfkb1,Rela 0.0011241425642107344
IL-1 pathway Elk1, Nfkb1, Rela 0.0012748952830245175
neurotrophic signaling Elk1, Nfkb1, Rela, Trp53 0.0012979014272467505
NGF —p75NTR→ p50:RelA-p65 Nfkb1, Rela 0.001400567221887963
CH000000333 Nfkb1, Rela 0.0017061874975544628
EDAR→ NF-kappaB Nfkb1, Rela 0.0017061874975544628
TNF-alpha→ p50:RelA-p65 Nfkb1, Rela 0.0024038320457071337
PDGF pathway Stat3, Stat5a, Stat5b 0.004038573581262634
TBK1:TRIF:IKK-i→ p50:RelA Nfkb1, Rela 0.004136568270131099
dsRNA→ p50:RelA Nfkb1, Rela 0.004136568270131099
RANKL→ p38 Nfkb1, Rela 0.004638374899213325
LAT→ p50:RelA Nfkb1, Rela 0.005722351182439321
EDAR pathway Nfkb1, Rela 0.009597224599851443
T-cell antigen receptor pathway Elk1, Nfkb1, Rela 0.009985935589865625
LPS→ NF-kappaB Nfkb1, Rela 0.011871624770568048
NF-kappaB→ genes encoding endothelial adhesion molecules Nfkb1,Rela 0.011871624770568048
Epo pathway Stat5a, Stat5b 0.012677905293747096
TLR9 pathway Nfkb1, Rela 0.012677905293747096
IL-1beta→ p50:RelA Nfkb1, Rela 0.01436112389208374
TLR3 pathway Nfkb1, Rela 0.018969411877391994
TNFR1 signaling Nfkb1, Rela 0.019957669453188952
diacyl lipopeptide, TLR2 Nfkb1, Rela 0.019957669453188952
p38 pathway Stat3, Trp53 0.029796036656231952
PRL pathway Stat5a, Stat5b 0.03343465884776058
p50:RelA-p65→ IL8 Nfkb1, Rela 0.03343465884776058
IL-3 signaling Stat5a, Stat5b 0.03343465884776058
TLR4 pathway Nfkb1, Rela 0.037242517103675384
TLR2-mediated signaling Nfkb1, Rela 0.04394876054564345
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TABLE 9 | Top three master regulators for three TF sets:
Intersection-specific TFs of the two cell lines, 1638N-T1-specific TFs and
CMT-93-specific TFs.
Rank Intersection set 1638N-T1-specific set CMT-93-specific set
1 Rad23A MLK3 Aebp1 (ACLP)
2 Smad3 TBK1 Il2rg (gamma-c)
3 Melk Siah2 Mapk1 (ERK2)
associated with metastasis in CRC, an outcome that is thought
to be dependent on chronic inflammation, e.g., triggered by
bacterial infection (Zhu et al., 1998; Maggio-Price et al., 2006).
The third master regulator maternal embryonic leucine zipper
kinase (Melk) is a known embryonic and neural stem cell marker
and belongs to the family of serine/threonine kinases (Choi and
Ku, 2011). Melk is normally expressed in cells that undergo
proliferation during embryonic development, however, elevated
expression has been particularly observed in variety of different
cancer cell types including colorectal cancer (Gray et al., 2005;
Badouel et al., 2010; Ganguly et al., 2015). Moreover, it has been
shown that Melk knockdown decreases proliferation and tumor
growth in CRC and, thus, it has been proposed to use Melk as a
therapeutic target for cancer (Gray et al., 2005).
The merged master regulatory network consisted
of 155 nodes (Figure 2, Supplementary Table S7 and
Supplementary Figure S7). The master regulators Rad23A
and Smad3 were found most upstream in the hierarchy of
the network. Rad23A was connected via the nodes p300 and
CBP to the other nodes in the network, whereas Smad3 was
connected to a variety of nodes which also included important
cancer-associated TFs such as c-Myc, Runt-related factors, and
Smad factors. Likewise, the master regulator Melk featured
cascades through several molecules including Smad factors and
p53 (see Figure 2 for more details).
3.5.2. Prediction of Master Regulators and
Construction of a Master Regulator Network Based
on the 1638N-T1-Specific TF Set
The master regulator analysis detected Mlk3, Tbk1 and
Siah2, which reach 28, 22, and 37 TFs from the 1638N-T1-
specific set, respectively. The first master regulator MLK3 is a
serine/threonine kinase that activates p38 MAP kinase, ERK, and
JNK signaling pathways (Velho et al., 2014). MLK3-mediated
activation has been shown to promote invasion and metastasis in
several cancer types, including breast and gastric cancers (Chen
et al., 2010; Mishra et al., 2010; Chen and Gallo, 2012; Cronan
et al., 2012). Moreover, it has been proposed that mutantMLK3 is
involved in the deregulation of several important CRC-associated
signaling pathways such as WNT, MAPK, NOTCH, TGF-β , and
P53 (Velho et al., 2014). Concerning Wnt signaling pathways in
MLK3 mutant cells, it has been shown that components of the
canonical Wnt pathway were found to be downregulated, while
components of the non-canonical planar cell polarity (PCP)
pathway were found to be upregulated.
The proposed master regulator TBK1 is a member of the
non-canonical IκB protein kinases which is involved in the
activation of IRF3 and c-Rel and NF-κB in cancer. The role of
TBK1 is poorly investigated in CRC. However, several studies
associated TBK1 with malignant transformation, cell growth and
proliferation (Chien et al., 2006; Kim et al., 2013a,b).
The third master regulator Siah2 is an E3 ubiquitin ligase
that regulates the degradation of a variety of substrates such
as the nuclear corepressor (N-CoR), TRAF2, 2-oxoglutarate
dehydrogenase-complex protein E2 (OGDC-E2), TIEG, and
β-catenin (Zhang et al., 1998; Matsuzawa and Reed, 2001;
Habelhah et al., 2002, 2004; Johnsen et al., 2002). Siah2 has
been implicated in MAPK signaling, mitochondrial dynamics
and cell survival (Nakayama et al., 2009; Kim et al., 2011). In
addition, several studies have indicated that Siah2 functions as a
proto-oncogene, while the Siah1 isoform has been associated with
tumor suppressor activity (Wong and Möller, 2013; Gopalsamy
et al., 2014). Although its role in CRC remains unclear, Siah2 has
been suggested to promote invasion and metastasis in a variety of
other cancers, including prostate, breast and liver (Qi et al., 2010,
2013; Behling et al., 2011; Malz et al., 2012; Sarkar et al., 2012;
Wong et al., 2012; Gopalsamy et al., 2014).
The merged master regulatory network consisted
of 52 nodes (Figure 3, Supplementary Table S8 and
Supplementary Figure S8). MLK3 and Siah2 were found
most upstream in the hierarchy of the network, whereas TBK1
was found downstream of the network branch which is regulated
by Siah2. MLK3 featured cascades through MKK3-isoform1, 4,
and 6, and IKK-alpha-isoform1, and -beta. Siah2 was connected
via the molecule alpha-synuclein-isoform1, Ubc5A, B, and C.
TBK1 was connected via IRF3, 5, and 7, STAT6, and IKK-beta to
its downstream nodes.
3.5.3. Prediction of Master Regulators and
Construction of a Master Regulator Network Based
on the CMT-93-Specific TF Set
For the CMT-93-specific TFs, the analysis reported the master
regulators Aebp1 (ACLP), Il2rg (gamma-c) and Mapk1 (ERK2),
which reach 43, 36, and 31 TFs from the set, respectively.
The first proposed master regulator, Aebp1, is known to act
as a transcriptional repressor in adipogenesis (Ladha et al.,
2012). Aebp1 is upregulated in the majority of the primary
glioblastoma multiforme (GBM) and loss of Aebp1 function was
shown to result in apoptosis (Ladha et al., 2012). Moreover,
Aebp1 induces NF-κB activity which leads to macrophage
inflammatory responsiveness and affects tumor cell growth and
survival (Majdalawieh et al., 2007). In the context of breast cancer
tumorigenesis, Aebp1 has been suggested to be involved in the
regulation of the cross-talk between mammary epithelium and
stroma (Holloway et al., 2012). To this date, the role of Aebp1
remains largely unclear in CRC.
The secondmaster regulator corresponded to the interleukin 2
receptor subunit gamma (Il2rg/gamma-c) which heterodimerizes
with several interleukin receptors, including receptors for the
interleukins −2, −4, −7, −9, −15, and −21 (Nata et al., 2015).
Interleukins receptor signaling pathways are known to play
crucial roles in inflammation-dependent progression and anti-
tumor responses in CRC (West et al., 2015).
The last master regulator Mapk1 (ERK2) belongs to the MAP-
kinases, which regulate cell growth, differentiation, proliferation,
migration, and apoptosis (Santarpia et al., 2012). MAPKs act
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downstream of several growth-factor receptors such as Egfr,
which are often found overexpressed and activated in CRC (Fang
and Richardson, 2005). Thus, it has been stated that the ERK
MAPK pathway plays a central role in the progression of CRC
(Fang and Richardson, 2005). In addition, it has been proposed
that this pathway but not the JNK pathway or the p38 MAPK
pathway is the key regulator of cell proliferation in CRC (Fang
and Richardson, 2005).
The merged master regulatory network was composed
of 65 nodes (Figure 4, Supplementary Table S9 and
Supplementary Figure S9). ACLP (Aebp1) and Il2rg (gamma-c)
were found to be the regulators most upstream in the network.
ACLP (Aebp1) was connected via the nodes ERK1 and TNF-
alpha to the other nodes in the network. The master regulator
Il2rg (gamma-c) featured a cascade through Jak3-isoform1,
whereas the master regulator Mapk1 (ERK2) was connected
to several molecules and TF families, including SREBP factors,
STAT factors and Ets-like factors (see Figure 4 for more details).
3.5.4. A Comparison with Randomly Selected Gene
Sets
To test the prediction quality of our results and, whether they
are specific for CRC, we performed a comparison between our
results and those found for randomly drawn gene sets. Thus,
we first randomly selected 10 gene sets, each of which had the
same sample size as the signature genes analyzed in this study.
After that, each random gene set was analyzed in the same
way as both signature gene sets. In this regard, we started with
TFBS enrichment analyses (see Section 2.4.1) for the detection
of enriched TFBSs in the promoter regions of each random
gene set. After retrieving the corresponding TFs, we observed
that 17 TFs were common to each of the 10 random gene
sets. Interestingly, 13 out of these 17 TFs were also detected
based on both CRC signature gene sets (see Section 3.4.1). To
determine their potential role in the context of our results, we
further searched for overrepresented TRANSPATH pathways
and master regulators based on these 13 TFs (see Section 2.4.2
and 2.4.3). The results of these analyses showed that there were
no overrepresented pathways and, beyond that, the master
regulators were completely different from those presented
in Section 3.5.1, 3.5.2, and 3.5.3. Finally, we searched for
overrepresented TRANSPATH pathways based on each random
gene set (see Section 2.3.2). As expected, the overrepresented
pathways found for each random gene set were completely
different among themselves and, thus, they have no overlap with
the pathways presented in the Section 3.3.1 and 3.3.2.
4. DISCUSSION
In this study, we specifically focused on revealing the similarities
and differences with respect to the transcriptional regulation
as well as the pathway repertoire of two distinct colorectal
cancer (CRC) cell lines, namely 1638N-T1 and CMT-93, in
a direct comparison. Based on signature genes that are most
significantly upregulated in cancer cell type I and cancer cell
type II, respectively, our approach aimed to identify the upstream
transcriptional regulators and their regulatory networks.
Our results indicated that many of the pathways, which
were identified based on the signature genes, can be linked to
both pro-tumor as well as anti-tumor properties. In particular,
we found pathways for 1638N-T1 which play a role in the
detoxification of carcinogens, immune response, and apoptosis.
Additionally, we found pathways which can be linked to oxidative
stress, inflammation, cell migration, proliferation and survival.
Oxidative stress is one important environmental factor in cancer
as it is genotoxic and contributes to mutations (Beckman and
Ames, 1997). During tumor progression, cells harbor mutations
that reduce growth-limiting effects in pathways such as TGF-
β signaling which becomes a tumor-promoting pathway due to
mutations in later stages of CRC (Jakowlew, 2006; Bellam and
Pasche, 2010; Calon et al., 2012). Therefore, it is likely that the
results include many putative anti-tumor pathways that contain
mutations in the cell lines, which is an important aspect to be
addressed in future investigations.
On the level of transcriptional regulation, we identified a
number of well-known, cancer-associated TFs with significantly
enriched binding sites in the promoter regions of the signature
genes. These TFs belong to a variety of TF families/subfamilies
and are known to form protein-protein interactions with each
other such as Jun factors and Fos factors which form the
heterodimeric AP-1 protein (Chen et al., 1996; Shaulian and
Karin, 2002; Eferl andWagner, 2003). Likewise, nuclear receptors
(NRs) of the subfamilies vitamin D receptors (NR1I) and retinoid
X receptors form the VDR-RXR heterodimer complex (Orlov
et al., 2012) that has been implicated in anticancer therapeutics
(Friedrich et al., 2002; Sepulveda et al., 2006; Deeb et al., 2007;
Matsuda and Kitagishi, 2013). In this light, it is known that
TFs do not regulate their target genes in solitude, but interact
with other TFs and cofactors in specific combinations for a
fine-tuned control of gene expression (Gerstein et al., 2012). In
addition, we identified different TF families/subfamilies that have
overlapping binding sites and may act in a synergistic, additive,
or antagonistic fashion in cancer. Kittler et al. revealed binding
redundancy for NRs and their putative cooperating TFs in breast
cancer on the basis of 39 factors, whereas non-overlapping
binding sites were found to occur rarely (Kittler et al., 2013).
Taken together, although the signature genes of both cell lines
show no overlap, they may still be regulated by common factors
in CRC.
We revealed that 62 and 72% of the TFs for 1638N-T1 and
CMT-93, respectively, were found in the intersection of both cell
lines. Consequently, only 38 and 28% of the TFs were exclusive
for 1638N-T1 and CMT-93, respectively, whose implications
in signal transduction pathways might explain phenotypic
differences between the two cell lines with regard to tumor
growth and metastasis. We deduced cross-talks between several
pathways that might have an impact on tumor progression in
the cell lines. For the APC-deficient 1638N-T1 cell line, we
found overrepresented pathways which related to the activation
of the canonical Wnt signaling pathway (Tables 1, 6). Wnt
signaling activity is known to contribute to tumor aggressiveness;
therefore, it is often targeted in cancer therapy (Anastas and
Moon, 2013; Loh et al., 2013). It has also been stated that
enhancement of canonical Wnt signaling activity is required
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FIGURE 5 | Schema for potential state of canonical Wnt signaling
pathway in mouse models. (A) Wnt signaling is activated in 1638N-T1. (B)
Wnt signaling is inhibited in CMT-93 through cross-talks with VDR- and/or
LXR-induced pathways. Interaction of tumor cells with the microenvironment
has an impact on cell proliferation, invasion, and metastasis in mouse models.
Signature genes and transcription factors/cofactors, whose binding sites were
found to be enriched in promoters, are indicated by a red asterisk or a yellow
asterisk, respectively.
for tumor progression and metastasis (Oguma et al., 2008).
On the other hand, we showed several pathways for CMT-93
which have been previously associated with an inhibition of Wnt
signaling. Two of these pathways related to VDR signaling and
LXR-induced signaling (Tables 4, 8). Strikingly, VDR and LXRα
(Nr1h3) were included in the signature genes for CMT-93 (see
Supplementary Table S2), and VDR also showed significantly
enriched binding sites (see Supplementary Table S5). Previous
studies have investigated the activation of VDR as well as LXR in
APC-deficient mice and observed that the activity of both factors
decreased tumor growth (Zheng et al., 2012; Sasso et al., 2013).
In addition, LXR expression was found to be downregulated in
colon tumors of APC-deficient mice compared with adjacent
normal mucosa (Su et al., 1992; Sasso et al., 2013). We also found
that CTNNB1, which encodes β-catenin, was not included in the
signature genes of any of the two cell lines, but showed significant
binding site enrichment (see Supplementary Table S6). With
respect to TCF-7-related factors, the genes Tcf7l1 and Lef1,
however, were included in the signature genes of 1638N-T1.
Interestingly, VDR and LXR can both directly bind to β-catenin,
thereby preventing β-catenin from binding to its target sites
(Uno et al., 2009; Makoukji et al., 2011; Zheng et al., 2012; Larriba
et al., 2013; Shackleford et al., 2013; Lim et al., 2014).
All things considered, supported by the knowledge that
1638N-T1 cells harbor a mutation in the APC gene, which
leads to aberrant Wnt pathway activation: we suggest that Wnt
signaling is activated in 1638N-T1, but inhibited in CMT-93
through cross-talks of canonical Wnt signaling with VDR
signaling pathway and/or LXR-related pathways. Consequently,
we suggest that Wnt signaling-driven tumor formation and
growth should be increased in mouse models involving
1638N-T1 compared to ones involving CMT-93. Though, many
additional factors have to be taken into account whenmonitoring
cell proliferation, invasion, and metastasis in mouse models.
Several previous studies indicated synergistic effects between
K-Ras and canonical Wnt signaling harboring APC mutations in
CRC (Janssen et al., 2006; Luo et al., 2009; Lemieux et al., 2015).
Furthermore, during development of effective cancer therapies,
tumor cells grown in vitro are transplanted into ectopic sites
of immunocompromized mice that do not reject tumor cells
(Sharpless and Depinho, 2006; Richmond and Su, 2008; Hung
et al., 2010). It has been stated that these xenograft models
may fail to recapitulate the heterogeneity of cancer and the
microenvironment, i.e., the interaction between tumor cells and
supporting stroma (Hung et al., 2010). In the end, regardless
of the fact that Wnt signaling may be aberrantly activated in
1638N-T1, a variety of different factors have an impact on the
capacity of tumor cells to grow, proliferate, and metastasize in
mouse models. We summarized our observations concerning
the potential state of canonical Wnt signaling in the cell lines
(Figure 5).
The master regulator analyses revealed several potential
candidates whichmight be useful as therapeutic targets for cancer
therapy. Master regulators were inferred from a network model
that explicitly displayed the regulatory cascades between TFs.
Beside several master regulators with yet unknown roles in CRC,
we found MLK3 and Mapk1 (ERK2) which might be important
in cancer cell proliferation, invasion, and metastasis of 1638N-
T1 and CMT-93, respectively. Above all, our master regulatory
networks can be used as models to generate testable hypotheses
for studying the phenotypic differences between 1638N-T1 and
CMT-93.
5. CONCLUSION
In this study, we have presented a systematic approach
which combines colorectal cancer (CRC) cell lines, namely
1638N-T1 and CMT-93, and well-established computational
methods in order to compare these cell lines on the level
of transcriptional regulation as well as on a pathway level,
i.e., the cancer cell-intrinsic pathway repertoire. We used
the Trinity platform and the geneXplain platform to identify
significantly upregulated genes in each of the cell lines as
well as their upstream transcriptional regulators, on the basis
of which we generated regulatory networks. Our findings
suggested that the Wnt signaling pathway is activated in 1638N-
T1, but inhibited in CMT-93 cells through cross-talks with
other pathways. Moreover, we identified a number of well-
known, cancer-associated TFs for both cell lines and provided
indication of several master regulators being present such as
MLK3 and Mapk1 (ERK2) which might be important in cell
proliferation, migration, and invasion of 1638N-T1 and CMT-93,
respectively. Using our systematic approach, we have provided
new insights into the invasive potential of individual CRC
cell lines, which can be used for development of effective
cancer therapy.
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